Open-label trial of imatinib mesylate in patients with unresectable recurrent glioblastoma multiforme expressing PDGFR (platelet-derived growth factor receptors).
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Imatinib (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 17 Dec 2009 Status changed from active, no longer recruiting to suspended as reported by ClinicalTrials.gov.
- 29 Oct 2005 New trial record.